<i>EML4-ALK</i> fusions are targetable oncogenic drivers in a subset of advanced non-small cell lung cancer (NSCLC) patients that can benefit from selected ALK inhibitors. This evidence concerns the gene EML4 and non-small cell lung carcinoma.